The Natural Products Association launches the first industry-driven program designed to test the purity and composition of Chinese raw ingredients, the group announces July 21. Testing of raw materials by the U.S. Pharmacopeia's Shanghai, China laboratory "represents a significant departure from the current process where U.S. companies must rely on a test by Chinese laboratories or test samples themselves in the United States," NPA says. Benefits to this system include "reduced transit times and costs; greater traceability and documentation of ingredients used in the supply chain; use of state-of-the-art technology in testing; and a systematic approach to verification," NPA states. The association opened a branch office in China last July and began developing the program shortly after, preceding the spate of problems linked to contaminated food products shipped from China, NPA says (1"The Tan Sheet" July 24, 2006, p. 3 and 2"The Tan Sheet" July 16, 2007, p. 5). NPA launched the program because there "seemed to be a logical connection to have people on the ground" to monitor and maintain product quality and reliability since China is one of the biggest ingredient sources, NPA Vice President Scientific and Regulatory Affairs Daniel Fabricant told "The Tan Sheet"...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.
